SYROS PHARMACEUTICALS, INC. Total Assets
SYROS PHARMACEUTICALS, INC. had Total Assets of $85.00 million as of 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2024-10-31
- 2024-09-30: Assets $85.00M.
- 2024-06-30: Assets $106.72M.
- 2024-03-31: Assets $134.73M.
- 2023-12-31: Assets $168.17M.
| Period end | Assets |
|---|---|
| 2024-09-30 | $85.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $106.72M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $134.73M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $168.17M 10-Q · filed 2024-10-31 |
| 2023-09-30 | $147.79M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $180.98M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $205.32M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $244.49M 10-K · filed 2024-03-27 |
| 2022-09-30 | $284.73M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $126.23M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $152.08M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $182.94M 10-K · filed 2023-03-02 |
| 2021-09-30 | $208.04M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $233.73M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $260.63M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $213.25M 10-K · filed 2022-03-15 |
| 2020-09-30 | $133.34M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $147.82M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $161.40M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $149.98M 10-K · filed 2021-03-04 |
| 2019-09-30 | $143.83M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $151.83M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $88.43M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $106.77M 10-K · filed 2020-03-05 |
| 2018-09-30 | $120.63M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $131.38M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $128.10M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $78.49M 10-K · filed 2019-03-07 |
| 2017-09-30 | $88.68M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $99.03M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $78.02M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $91.32M 10-K · filed 2018-03-12 |
| 2016-09-30 | $100.41M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $60.95M 10-Q · filed 2016-08-15 |
| 2015-12-31 | $43.63M 10-K · filed 2017-03-20 |